4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(1-oxy-pyridin-3-yl)-phenyl]-amide | 915006-01-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(1-oxy-pyridin-3-yl)-phenyl]-amide
• 英文别名: 4-cyano-N-[2-(cyclohexen-1-yl)-4-(1-oxidopyridin-1-ium-3-yl)phenyl]-1-(2-trimethylsilylethoxymethyl)imidazole-2-carboxamide
• CAS: 915006-01-8
• 化学式: C₂₈H₃₃N₅O₃Si
• 分子量: 515.687
• InChiKey: RWAHFAJYQVJDRA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.58
• 重原子数：
  37
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  105
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(1-oxy-pyridin-3-yl)-phenyl]-amide 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 4-cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(1-oxy-pyridin-3-yl)-phenyl]-amide
  参考文献：
  名称：

  Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors

  摘要：

  During efforts to improve the bioavailability of FMS kinase inhibitors 1 and 2, a series of saturated and aromatic 4-heterocycles of reduced basicity were prepared and evaluated in an attempt to also improve the cardiovascular safety profile over lead arylamide 1, which possessed ion channel activity. The resultant compounds retained excellent potency and exhibited diminished ion channel activity. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.05.013
• 作为产物：
  描述：

  3-溴吡啶-N-氧化物 、 4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)-phenyl]-amide 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 生成 4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(1-oxy-pyridin-3-yl)-phenyl]-amide
  参考文献：
  名称：

  Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors

  摘要：

  During efforts to improve the bioavailability of FMS kinase inhibitors 1 and 2, a series of saturated and aromatic 4-heterocycles of reduced basicity were prepared and evaluated in an attempt to also improve the cardiovascular safety profile over lead arylamide 1, which possessed ion channel activity. The resultant compounds retained excellent potency and exhibited diminished ion channel activity. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.05.013

文献信息

• Reducing ion channel activity in a series of 4-heterocyclic arylamide FMS inhibitors
  作者：Kenneth J. Wilson、Carl R. Illig、Jinsheng Chen、Mark J. Wall、Shelley K. Ballentine、Renee L. DesJarlais、Yanmin Chen、Carsten Schubert、Robert Donatelli、Ioanna Petrounia、Carl S. Crysler、Christopher J. Molloy、Margery A. Chaikin、Carl L. Manthey、Mark R. Player、Bruce E. Tomczuk、Sanath K. Meegalla

  DOI：10.1016/j.bmcl.2010.05.013

  日期：2010.7

  During efforts to improve the bioavailability of FMS kinase inhibitors 1 and 2, a series of saturated and aromatic 4-heterocycles of reduced basicity were prepared and evaluated in an attempt to also improve the cardiovascular safety profile over lead arylamide 1, which possessed ion channel activity. The resultant compounds retained excellent potency and exhibited diminished ion channel activity. (c) 2010 Elsevier Ltd. All rights reserved.